Center for Intellectual Property x Innovation Policy (C-IP2)

Center for Intellectual Property x Innovation Policy

Center for Intellectual Property x Innovation Policy

C-IP 2 produces research, education, and service at the intersection of IP and innovation policy to better understand and shape the means of innovation as a positive force for good. We do so by promoting a diverse set of perspectives and voices to present a fuller picture than that of the dominant legal academic literature on the role of IP and other legal mechanisms to transform great ideas into useful or aesthetic artifacts and activities.

IN THE SPOTLIGHT

C-IP 2 Annual Fall Conference

The Importance of Exclusive Rights

Thursday, October 17, &
Friday, October 18, 2024

Hosted in person at Mason Square Campus
in Arlington, VA

— VA CLE: Approval TBD for 7 Hours —

C-IP 2 ’s 2024 Annual Conference will explore the importance of exclusive rights in the patent and copyright industries, the historical basis for those rights, and what happens to innovators and creators if the rights are not protected.

We are pleased to announce that this year’s conference will feature Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO) Kathi Vidal as our Keynote speaker on Friday, October 18.

New Blog Post by Prof. Justin Hughes

— Read the Blog Post in Full —

A new blog post from Professor Justin Hughes (Hon. William Matthew Byrne, Jr. Distinguished Professor of Law; Fulbright-Hanken Distinguished Chair in Business and Economics, Loyola University School of Law) discusses the “NO FAKES Act: Unpacking the New Bipartisan Bill on Digital Replicas.”

This post was originally published on the Patently-O blog and is cross-posted here with permission from both Patently-O and the author.

New Blog Post on AI and Authorship

— Read the Blog Post in Full —

silver copyright symbol

A new blog post from Molly Torsen Stech discusses the idea that “Authors are Humans and Creativity is a Function of Humanness: What the Mannion Court Can Teach Us About Generative AI’s Relationship to Authorship” and features her forthcoming paper Copyright Thickness, Thinness, and a Mannion Test for Images Produced by Generative Artificial Intelligence Applications.

In Response to the PTO

— Read the Response in Full —

Folder tab reading

“In Response to Notice of Proposed Rulemaking on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting”: Professor Emily Michiko Morris, Professor Mark F. Schultz, and Joshua Kresh have filed comments objecting to the USPTO’s “proposed changes to terminal disclaimers and their use to overcome obviousness-type double patenting objections.”

C-IP 2 Summer 2024 Progress Report
(March – May 2024)

See what C-IP 2 and our Friends and Affiliates have been
doing, saying, and writing over the past several months!

— Read the Report in Full —

New Blog Post:
“Pharmaceutical ‘Nominal Patent Life’ Versus ‘Effective Patent Life,’ Revisited”

By Emily Michiko Morris & Joshua Kresh

— Read the Blog Post in Full —

Overlaid images of pills, a gloved hand of someone expecting a pill, and an eyedropper

Executive summary: Many critics of pharmaceutical companies argue that they abuse the patent system through “evergreening” or “thickets” to increase the amount of time they can avoid generic competition and keep drug prices high. Those critics have not looked at the real-world effects of pharmaceutical patents on generic entry, however. Our review of actual time to generic entry for more than one hundred of 2012’s top-selling drugs shows that: